journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer | Page 2

journal
https://read.qxmd.com/read/31320002/sensitivity-of-next-generation-sequencing-assays-detecting-oncogenic-fusions-in-plasma-cell-free-dna
#21
Julianna G Supplee, Marina S D Milan, Lee P Lim, Kristy T Potts, Lynette M Sholl, Geoffrey R Oxnard, Cloud P Paweletz
OBJECTIVES: Plasma genotyping represents an opportunity for convenient detection of clinically actionable mutations in advanced cancer patients, such has been well-documented in non-small cell lung cancer (NSCLC). Oncogenic gene fusions are complex variants that may be more challenging to detect by next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA). Rigorous evaluation of plasma NGS assays in the detection of fusions is needed to maximize clinical utility. MATERIALS AND METHODS: Additional plasma was collected from patients with advanced NSCLC and ALK, ROS1, or RET gene fusions in tissue who had undergone clinical plasma NGS using Guardant360™ (G360, Guardant Health)...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31320001/endobronchial-and-surgical-treatment-of-pulmonary-carcinoid-tumors-a-systematic-literature-review
#22
REVIEW
E M B P Reuling, C Dickhoff, P W Plaisier, H J Bonjer, J M A Daniels
The treatment of pulmonary carcinoid has changed over the last decades. Although surgical resection is still the gold standard, minimally invasive endobronchial procedures have emerged as a parenchyma sparing alternative for tumors located in the central airways. This review was performed to identify the optimal treatment strategy for pulmonary carcinoid, with a particular focus on the feasibility and outcome of parenchyma sparing techniques versus surgical resection. A systematic review of the literature was carried out using MEDLINE, Embase and the Cochrane databases, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31320000/heterogeneity-of-pd-l1-expression-in-non-small-cell-lung-cancer-implications-for-specimen-sampling-in-predicting-treatment-response
#23
Alexander Haragan, John K Field, Michael P A Davies, Carles Escriu, Aaron Gruver, John R Gosney
OBJECTIVES: PD-L1 expression on tumour cells can guide the use of anti-PD-1/PD-L1 immune modulators to treat patients with non-small cell lung cancer (NSCLC). Heterogeneity of PD-L1 expression both within and between tumour sites is a well-documented phenomenon that compromises its predictive power. Our aim was to better characterise the pattern and extent of PD-L1 heterogeneity with a view to optimising tumour sampling and improve its accuracy as a biomarker. MATERIALS AND METHODS: Expression of PD-L1 was assessed by immunochemistry using the SP263 clone in 107 resected primary NSCLCs and their nodal metastases...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319999/clinical-utility-of-plasma-based-digital-next-generation-sequencing-in-oncogene-driven-non-small-cell-lung-cancer-patients-with-tyrosine-kinase-inhibitor-resistance
#24
Jon Zugazagoitia, Ana Gómez-Rueda, Eloisa Jantus-Lewintre, Dolores Isla, Carlos Camps, Inmaculada Ramos, Jose Manuel Trigo, Reyes Bernabé, Oscar Juan-Vidal, Jose Miguel Sanchez-Torres, Rosario García-Campelo, Mariano Provencio, Enriqueta Felip, Javier de Castro, Iris Faull, Richard B Lanman, Santiago Ponce-Aix, Luis Paz-Ares, Pilar Garrido
OBJECTIVES: Resistance to tyrosine-kinase inhibitors (TKIs) is a clinical challenge in patients with oncogene-driven non-small-cell lung cancers (NSCLC). We have analyzed the utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) to impact the clinical care of patients with TKI resistance. MATERIALS AND METHODS: We conducted a multi-institutional prospective study including consecutive EGFR, ALK, or ROS1-altered NSCLC patients with TKI resistance from 12 Spanish institutions...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319998/paired-genomic-analysis-of-squamous-cell-carcinoma-transformed-from-egfr-mutated-lung-adenocarcinoma
#25
Sehhoon Park, Joon Ho Shim, Boram Lee, Inju Cho, Woong-Yang Park, Youjin Kim, Se-Hoon Lee, Yoon La Choi, Joungho Han, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
OBJECTIVES: Adenocarcinoma (ADC) to squamous cell carcinoma (SCC) transformation (AST) is reported in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer after tyrosine kinase inhibitor (TKI) failure. However, little is known about the underlying genomic changes during the AST process. MATERIALS AND METHODS: We retrospectively reviewed our tissue database collected after first- or second- generation EGFR TKI resistance (n = 263) and identified 3 cases of AST...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319997/evaluation-of-a-health-service-adopting-proactive-approach-to-reduce-high-risk-of-lung-cancer-the-liverpool-healthy-lung-programme
#26
Bhagabati Ghimire, Roberta Maroni, Daniel Vulkan, Zoheb Shah, Edward Gaynor, Michelle Timoney, Lisa Jones, Rachel Arvanitis, Martin Ledson, Linda Lukehirst, Paul Rutherford, Faye Clarke, Katy Gardner, Michael W Marcus, Sarah Hill, Darcy Fideo, Sabrina Mason, Samuel G Smith, Samantha L Quaife, Karen Fitzgerald, Veronique Poirier, Stephen W Duffy, John K Field
OBJECTIVES: This Liverpool Healthy Lung Programme is a response to high rates of lung cancer and respiratory diseases locally and aims to diagnose lung cancer at an earlier stage by proactive approach to those at high risk of lung cancer. The objective of this study is to evaluate the programme in terms of its likely effect on mortality from lung cancer and its delivery to deprived populations. METHODS: Persons aged 58-75 years, with a history of smoking or a diagnosis of chronic obstructive pulmonary disease (COPD)2 according to general practice records were invited for lung health check in a community health hub setting...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319996/early-serum-tumor-marker-dynamics-predict-progression-free-and-overall-survival-in-single-pd-1-pd-l1-inhibitor-treated-advanced-nsclc-a-retrospective-cohort-study
#27
David Lang, Andreas Horner, Elmar Brehm, Kaveh Akbari, Benedikt Hergan, Klaus Langer, Christian Asel, Mario Scala, Bernhard Kaiser, Bernd Lamprecht
OBJECTIVES: To evaluate serum tumor markers (STM) as biomarkers for treatment monitoring and prognosis in advanced non-small cell lung cancer (NSCLC) treated with single-agent PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy. MATERIALS AND METHODS: Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cytokeratin-19 fragments (CYFRA 21-1) and neuron specific enolase (NSE) were routinely measured at NSCLC diagnosis, initially elevated markers were used for follow-up...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319995/guideline-adherence-of-mediastinal-staging-of-non-small-cell-lung-cancer-a-multicentre-retrospective-analysis
#28
Jelle E Bousema, Martijn van Dorp, Fieke Hoeijmakers, Ilse A Huijbregts, Nicole P Barlo, Gerben P Bootsma, WimJan P van Boven, Niels J M Claessens, Anne-Marie C Dingemans, Wessel E Hanselaar, Robert Th J Kortekaas, Jan-Willem H P Lardenoije, Jos G Maessen, W Hermien Schreurs, Yvonne Vissers, Maggy Youssef-El Soud, Marcel G W Dijkgraaf, JoukeT Annema, Frank J C van den Broek
OBJECTIVES: Mediastinal lymph node staging of NSCLC by initial endosonography and confirmatory mediastinoscopy is recommended by the European guideline. We assessed guideline adherence on mediastinal staging, whether staging procedures were performed systematically and unforeseen N2 rates following staging by endosonography with or without confirmatory mediastinoscopy. MATERIAL AND METHODS: We performed a multicentre (n = 6) retrospective analysis of NSCLC patients without distant metastases, who were surgical candidates and had an indication for mediastinal staging in the year 2015...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319994/a-phase-ib-study-of-the-combination-of-afatinib-and-ruxolitinib-in-egfr-mutant-nsclc-with-progression-on-egfr-tkis
#29
Ji Soo Park, Min Hee Hong, You Jin Chun, Hye Ryun Kim, Byoung Chul Cho
OBJECTIVES: We evaluated the safety and efficacy of the combination therapy of afatinib, an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and ruxolitinib, a JAK1/2 selective inhibitor, in patients with EGFR mutant NSCLC progressing on at least one kind of EGFR-TKI. MATERIALS AND METHODS: In this phase Ib open-label study, we used a 3 + 3 dose-escalation design. Patients with histologically diagnosed EGFR-mutant stage IV NSCLC and documented disease progression on EGFR-TKI therapies were enrolled...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319993/impact-of-keap1-nfe2l2-cul3-mutations-on-duration-of-response-to-egfr-tyrosine-kinase-inhibitors-in-egfr-mutated-non-small-cell-lung-cancer
#30
Jessica A Hellyer, Henning Stehr, Millie Das, Sukhmani K Padda, Kavitha Ramchandran, Joel W Neal, Maximilian Diehn, Heather A Wakelee
OBJECTIVES: For patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), frontline EGFR-tyrosine kinase inhibitor (TKI) therapy compared to chemotherapy improves outcomes. However, resistance to these agents uniformly develops. Recently, mutations in the KEAP1-NFE2L2 pathway have been implicated as a potential mechanism of acquired EGFR TKI resistance. MATERIALS AND METHODS: We examined all patients with metastatic NSCLC with mutations in both EGFR and KEAP1/NFE2L2/CUL3 identified on next generation sequencing from 2015 - 2018...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319992/variation-in-the-time-to-treatment-for-stage-iii-and-iv-non-small-cell-lung-cancer-patients-for-hospitals-in-the-netherlands
#31
M van de Ven, V P Retèl, H Koffijberg, W H van Harten, M J IJzerman
OBJECTIVES: Increased emphasis on molecular diagnostics can lead to increased variation in time to treatment (TTT) for patients with stage III and IV non-small cell lung cancer. This article presents the variation in TTT for advanced NSCLC patients observed in Dutch hospitals before the widespread use of immunotherapy. The aim of this article was to explore the variation in TTT between patients, as well as between hospitals. MATERIAL AND METHODS: Based on the Netherlands Cancer Registry, we used patient-level data (n = 4096) from all 78 hospitals that diagnosed stage III or IV NSCLC in the Netherlands in 2016...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319991/immune-checkpoint-inhibitors-and-chemoradiation-in-stage-iii-unresectable-non-small-cell-lung-cancer
#32
REVIEW
Barbara Melosky, Rosalyn Juergens, Deanna McLeod, Natasha Leighl, Anthony Brade, Paul B Card, Quincy Chu
Lung cancer resulted in an estimated 1.8 million deaths worldwide in 2018 and approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III unresectable disease. Phase III data from the PACIFIC trial show significantly improved progression-free survival for the checkpoint-inhibitor durvalumab given as consolidation following definitive chemoradiotherapy (cCRT). Overall survival results from this study have now been reported, along with outcomes from other phase II trials...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319990/upstaging-centrality-and-survival-in-early-stage-non-small-cell-lung-cancer-video-assisted-surgery
#33
M Boada, R Guzmán, M Montesinos, A Libreros, A Guirao, D Sánchez-Lorente, J M Gimferrer, A Agustí, L Molins
OBJECTIVES: Hiliar (pN1) and mediastinal lymph (pN2) nodal upstaging after surgery for early stage (<IIB) non-small cell lung cancer (NSCLC) is a quality marker of surgical lymphadenectomy. It has been suggested that Video-Assisted Thoracoscopic Surgery (VATS) may result in suboptimal lymphadenctomy because nodal upstaging was lower than after open thoracothomy (THO). We sought to: (1) compare the prevalence of nodal upstaging after VATS and THO in NSCLC < IIB; (2) investigate potential risk factors of nodal upstaging; and, (3) assess the impact of nodal upstaging on survival...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319989/ct-screening-for-lung-cancer-are-we-ready-to-implement-in-europe
#34
REVIEW
Haval Balata, Matthew Evison, Anna Sharman, Philip Crosbie, Richard Booton
Lung cancer screening with low-dose CT (LDCT) is already available in certain parts of the world, such as the United States, but not yet in Europe. The recently published European position statement on lung cancer screening has recommended planning for implementation of screening to start within 18-months [1]. Pilot European programmes are already underway, primarily in the United Kingdom (UK), delivering lung cancer screening to their local populations. This review article acknowledges the evidence base for LDCT screening and will discuss the challenges that still need to be overcome in an attempt to answer the question: are we ready to implement in Europe?...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319988/first-line-immune-checkpoint-blockade-for-advanced-non-small-cell-lung-cancer-travelling-at-the-speed-of-light
#35
REVIEW
Christoph Jakob Ackermann, Martin Reck, Luis Paz-Ares, Fabrice Barlesi, Raffaele Califano
The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319987/characterization-of-lung-adenocarcinoma-with-a-cribriform-component-reveals-its-association-with-spread-through-air-spaces-and-poor-outcomes
#36
Qifeng Ding, Donglai Chen, Xiaofan Wang, Junmiao Wen, Chang Chen, Yongsheng Zhang, Zhonghua Xu, Yongbing Chen
OBJECTIVE: To further investigate the relationship between the cribriform component and spread through air spaces (STAS), and to unravel the potential pathological mechanism of poor prognoses in lung adenocarcinoma (LUAD) patients with a cribriform component. METHODS: We retrospectively reviewed the clinicopathological characteristics of 208 LUADs. The cribriform component was identified by hematoxylin and eosin staining. The identification of STAS referred to our previous study...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319986/novel-multiplex-droplet-digital-pcr-assay-for-scoring-pd-l1-in-non-small-cell-lung-cancer-biopsy-specimens
#37
Amanda Vannitamby, Shona Hendry, Louis Irving, Daniel Steinfort, Steven Bozinovski
OBJECTIVES: Immune checkpoint inhibitors have become integrated into the clinical management of non-small cell lung cancer (NSCLC). Using RTqPCR, we have previously identified a gene expression panel that detected presence of malignant cells (MMP9:TIMP3 ratio) and quantified PD-L1 transcript levels in small biopsy specimens. However, RTqPCR has diagnostic limitations as it does not generate absolute copy number and is not readily multiplexed. To address this, we have developed a multiplex droplet digital PCR (ddPCR) assay...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319985/identification-and-monitoring-of-somatic-mutations-in-circulating-cell-free-tumor-dna-in-lung-cancer-patients
#38
Ilaria Francaviglia, Gilda Magliacane, Chiara Lazzari, Greta Grassini, Emanuela Brunetto, Elena Dal Cin, Salvatore Girlando, Daniela Medicina, Chanel Elisha Smart, Alessandra Bulotta, Vanesa Gregorc, Lorenza Pecciarini, Claudio Doglioni, Maria Giulia Cangi
OBJECTIVES: Circulating cell-free tumor DNA (ctDNA) isolated from the peripheral blood of non-small-cell lung cancer (NSCLC) patients provides biomarkers for both therapeutic target selection, particularly when direct tumor biopsy is unfeasible, and also for drug resistance monitoring. This study evaluates the reliability and feasibility of ctDNA analysis in an in-house clinical molecular diagnostic workflow. MATERIALS AND METHODS: Mutation profiling by both standard methods and Next-Generation sequencing (NGS) was carried out and compared on 2 independent lung cancer patient cohorts...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319984/the-incidence-of-lymph-node-metastasis-in-patients-with-different-oncogenic-driver-mutations-among-t1-non-small-cell-lung-cancer
#39
Zhichao Liu, Hengrui Liang, Jie Lin, Xiuyu Cai, Zhenkui Pan, Jun Liu, Xiaohong Xie, Caichen Li, Bo Cheng, Yi Zhao, Jianxing He, Wenhua Liang
OBJECTIVE: To investigate the incidence and distribution of lymph node metastasis in patients with different gene mutations among pathological T1 non-small-cell lung cancers (NSCLC). METHODS: NSCLC cases resected in our institution between 2016 and 2018 were included. Driver mutation testing was performed in all resected tumor tissues. These patients were grouped by the type of gene mutations. On the basis of protein that mutant-genes encoded involved in the molecular pathway, the genotypes were further classified into four distinct groups: upstream receptor mutant protein (EGFR, HER2 and MET); downstream regulator mutant protein (KRAS and BRAF); fusion mutant protein (ROS1, ALK and RET) and the wild type group...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31319983/final-results-of-the-seneca-second-line-nintedanib-in-non-small-cell-lung-cancer-trial
#40
Enrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, Rita Chiari, Francesco Grossi, Marcello Tiseo, Francesco Di Costanzo, Angelo Delmonte, Gianpiero Romano, Domenico Galetta, Vieri Scotti, Vanesa Gregorc, Salvatore Pisconti, Giovanni Luca Ceresoli, Alessandro Del Conte, Libero Ciuffreda, Ida Colantonio, Emilio Bria, Serena Ricciardi, Anna Manzo, Giulio Metro, Anna Maria Morelli, Rossana Critelli, Maria Vittoria Pacchiana, Ilaria Stura, Giuseppe Migliaretti, Silvia Novello
OBJECTIVES: Despite the scant docetaxel's tolerability, second-line association with nintedanib still represents a standard-of-care for non-squamous non-small cell lung cancer (nsNSCLC), giving to rapidly-progressing patients the greatest survival advantage. The SENECA trial is a phase IIb, open-label, study evaluating whether nintedanib/docetaxel can be equally effective and safe regardless docetaxel schedule. MATERIALS AND METHODS: Recurrent nsNSCLC patients were stratified into cohort 1 and 2, according to relapse-time (within or over 3 months) from end of first-line chemotherapy...
August 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
2
3
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"